Floatz logo

Lamivudine

Hepatitis

Novartis PharmaceuticalsSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

6 Active assets in the Hepatitis cohort.

Asset / SponsorPhaseRating
MIDAZOLAM
Erasme University Hospital
Phase 4BB
Meperidine
Erasme University Hospital
Phase 4BB
Orlistat
St. Louis University
Phase 4BB
Entecavir
Cttq
Phase 4BB
URSODEOXYCHOLIC ACID
West China Hospital
Phase 4BB

View all 31 →

Same molecule, other indications

Lamivudine is also rated in:

lipodystrophyDormant
BBB
Indicative ·
78 / 100
View asset →
HIV infectious diseaseDormant
BBB
Indicative ·
74 / 100
View asset →
chronic hepatitis B virus infectionDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →